INTRODUCTION: Even as substantial improvements have been made in human epidermal growth factor receptor 2 (HER2)-targeted therapies since the approval of trastuzumab more than 20 years ago, there is still a considerable unmet need in patients with HER2-expressing breast cancer (BC) and other solid tumors. Trastuzumab deruxtecan (T-DXd) is a newer antibody-drug conjugate approved for the treatment of metastatic breast cancer (BC) and gastric cancer (GC) and is under active investigation in other solid tumors, including non-small cell lung cancer, colorectal cancer, and HER2-low-expressing tumors.AREAS COVERED: The current treatment and investigational landscape of HER2-positive and HER2-low metastatic BC (mBC) and the preclinical and clinical trials investigating T-DXd. To identify relevant literature, a search was performed on English-language publications and congress abstracts.EXPERT OPINION: T-DXd is likely to become the standard of care for second-line treatment of HER2-positive mBC, and it may play a role in the treatment of hormone receptor-positive and triple-negative mBC with HER2-low expression. Because it was recently approved in the United States and Japan to treat HER2-positive metastatic GC, it holds promise for the treatment of other HER2-positive solid tumors, including colorectal cancer, non-small cell lung cancer, and HER2-low-expressing BC.
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond / J. Perez, L. Garrigós, M. Gion, P.A. Jänne, K. Shitara, S. Siena, J. Cortés. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - (2021 Apr 01). [Epub ahead of print]
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
S. Siena;
2021
Abstract
INTRODUCTION: Even as substantial improvements have been made in human epidermal growth factor receptor 2 (HER2)-targeted therapies since the approval of trastuzumab more than 20 years ago, there is still a considerable unmet need in patients with HER2-expressing breast cancer (BC) and other solid tumors. Trastuzumab deruxtecan (T-DXd) is a newer antibody-drug conjugate approved for the treatment of metastatic breast cancer (BC) and gastric cancer (GC) and is under active investigation in other solid tumors, including non-small cell lung cancer, colorectal cancer, and HER2-low-expressing tumors.AREAS COVERED: The current treatment and investigational landscape of HER2-positive and HER2-low metastatic BC (mBC) and the preclinical and clinical trials investigating T-DXd. To identify relevant literature, a search was performed on English-language publications and congress abstracts.EXPERT OPINION: T-DXd is likely to become the standard of care for second-line treatment of HER2-positive mBC, and it may play a role in the treatment of hormone receptor-positive and triple-negative mBC with HER2-low expression. Because it was recently approved in the United States and Japan to treat HER2-positive metastatic GC, it holds promise for the treatment of other HER2-positive solid tumors, including colorectal cancer, non-small cell lung cancer, and HER2-low-expressing BC.File | Dimensione | Formato | |
---|---|---|---|
Trastuzumab deruxtecan in HER2 positive metastatic breast cancer and beyond.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
903.86 kB
Formato
Adobe PDF
|
903.86 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.